Lilly withdraws from EU rolling review of COVID-19 antibodies
Nov 2 (Reuters) - The European Union's drug regulator said on Tuesday it had ended the rolling review of COVID-19 antibody-based treatments developed by Eli Lilly after the U.S.-based drugmaker withdrew from the process https://www.ema.europa.eu/en/news/ema-ends-rolling-review-antibodies-bamlanivimab-etesevimab-covid-19-following-withdrawal-lilly.
Lilly's letter https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-bamlanivimab-etesevimab_.pdf to the European Medicines Agency (EMA), dated Oct. 29, said that "at this point Lilly is not in a position to generate the additional data required by the CHMP (EMA's human medicines committee) to progress to a formal marketing authorization application." (Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva)
